S&P 500   3,232.26 (-2.63%)
DOW   26,722.44 (-3.38%)
QQQ   261.72 (-1.93%)
AAPL   105.37 (-1.38%)
MSFT   197.71 (-1.34%)
FB   246.08 (-2.55%)
GOOGL   1,412.82 (-2.64%)
AMZN   2,892.88 (-2.10%)
NVDA   481.84 (-1.18%)
TSLA   429.46 (-2.87%)
BABA   267.06 (-1.96%)
CGC   15.56 (-4.89%)
MU   48.51 (-4.39%)
GE   6.30 (-8.43%)
AMD   75.60 (+0.89%)
T   28.50 (-1.49%)
F   6.87 (-4.98%)
ACB   6.22 (-4.75%)
GILD   63.59 (-2.24%)
NFLX   472.23 (+0.48%)
DIS   124.08 (-3.54%)
BAC   24.22 (-3.93%)
BA   154.96 (-3.84%)
S&P 500   3,232.26 (-2.63%)
DOW   26,722.44 (-3.38%)
QQQ   261.72 (-1.93%)
AAPL   105.37 (-1.38%)
MSFT   197.71 (-1.34%)
FB   246.08 (-2.55%)
GOOGL   1,412.82 (-2.64%)
AMZN   2,892.88 (-2.10%)
NVDA   481.84 (-1.18%)
TSLA   429.46 (-2.87%)
BABA   267.06 (-1.96%)
CGC   15.56 (-4.89%)
MU   48.51 (-4.39%)
GE   6.30 (-8.43%)
AMD   75.60 (+0.89%)
T   28.50 (-1.49%)
F   6.87 (-4.98%)
ACB   6.22 (-4.75%)
GILD   63.59 (-2.24%)
NFLX   472.23 (+0.48%)
DIS   124.08 (-3.54%)
BAC   24.22 (-3.93%)
BA   154.96 (-3.84%)
S&P 500   3,232.26 (-2.63%)
DOW   26,722.44 (-3.38%)
QQQ   261.72 (-1.93%)
AAPL   105.37 (-1.38%)
MSFT   197.71 (-1.34%)
FB   246.08 (-2.55%)
GOOGL   1,412.82 (-2.64%)
AMZN   2,892.88 (-2.10%)
NVDA   481.84 (-1.18%)
TSLA   429.46 (-2.87%)
BABA   267.06 (-1.96%)
CGC   15.56 (-4.89%)
MU   48.51 (-4.39%)
GE   6.30 (-8.43%)
AMD   75.60 (+0.89%)
T   28.50 (-1.49%)
F   6.87 (-4.98%)
ACB   6.22 (-4.75%)
GILD   63.59 (-2.24%)
NFLX   472.23 (+0.48%)
DIS   124.08 (-3.54%)
BAC   24.22 (-3.93%)
BA   154.96 (-3.84%)
S&P 500   3,232.26 (-2.63%)
DOW   26,722.44 (-3.38%)
QQQ   261.72 (-1.93%)
AAPL   105.37 (-1.38%)
MSFT   197.71 (-1.34%)
FB   246.08 (-2.55%)
GOOGL   1,412.82 (-2.64%)
AMZN   2,892.88 (-2.10%)
NVDA   481.84 (-1.18%)
TSLA   429.46 (-2.87%)
BABA   267.06 (-1.96%)
CGC   15.56 (-4.89%)
MU   48.51 (-4.39%)
GE   6.30 (-8.43%)
AMD   75.60 (+0.89%)
T   28.50 (-1.49%)
F   6.87 (-4.98%)
ACB   6.22 (-4.75%)
GILD   63.59 (-2.24%)
NFLX   472.23 (+0.48%)
DIS   124.08 (-3.54%)
BAC   24.22 (-3.93%)
BA   154.96 (-3.84%)
Log in
AMEX:SLS

SLS International Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Read More
SLS International logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+1-417-8834549

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SLS International (AMEX:SLS) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of SLS International?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SLS International in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SLS International
.

How were SLS International's earnings last quarter?

SLS International Inc (AMEX:SLS) posted its earnings results on Thursday, August, 13th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.02.
View SLS International's earnings history
.

When did SLS International's stock split? How did SLS International's stock split work?

SLS International shares reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of SLS International stock prior to the reverse split would have 2 shares after the split.

What price target have analysts set for SLS?

1 brokers have issued twelve-month price targets for SLS International's shares. Their forecasts range from $12.00 to $12.00. On average, they expect SLS International's stock price to reach $12.00 in the next year.
View analysts' price targets for SLS International
.

Who are some of SLS International's key competitors?

What other stocks do shareholders of SLS International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SLS International investors own include Unilife (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Sunesis Pharmaceuticals (SNSS), Novavax (NVAX), Athersys (ATHX), Catalyst Pharmaceuticals (CPRX) and Fission Uranium (FCUUF).

Who are SLS International's key executives?

SLS International's management team includes the following people:
  • Dr. Angelos M. Stergiou M.D., ScD h.c., Founder, Pres, CEO & Director (Age 44, Pay $962.5k)
  • Mr. John Thomas Burns CPA, CPA, VP of Fin. & Corp. Controller & Interim Principal Accounting Officer (Age 35, Pay $338.45k)
  • Ms. Barbara A. Wood, Exec. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $525.49k)
  • Mr. Martin G. Baum, Chief Operating Officer (Age 54)
  • Dr. Dragan Cicic, Sr. VP of Clinical Devel. (Age 57)

What is SLS International's stock symbol?

SLS International trades on the AMEX under the ticker symbol "SLS."

How do I buy shares of SLS International?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SLS International's official website?

The official website for SLS International is www.sls-international.com.

How can I contact SLS International?

SLS International's mailing address is 3119 S Scenic Ave, SPRINGFIELD, MO 65807-3926, United States. The biotechnology company can be reached via phone at +1-417-8834549 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.